Compare DFIN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | TRVI |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2017 | 2019 |
| Metric | DFIN | TRVI |
|---|---|---|
| Price | $49.53 | $11.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $61.50 | $20.38 |
| AVG Volume (30 Days) | 312.7K | ★ 1.1M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $963,000,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $3.87 | N/A |
| P/E Ratio | $42.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.07 | $4.85 |
| 52 Week High | $66.25 | $14.39 |
| Indicator | DFIN | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 43.88 |
| Support Level | $44.35 | $10.04 |
| Resistance Level | $55.58 | $11.78 |
| Average True Range (ATR) | 2.08 | 0.73 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 40.74 | 8.00 |
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.